SOURCE: Daxor Corp.

July 14, 2008 08:30 ET

Daxor Announces Quarterly Dividend

NEW YORK, NY--(Marketwire - July 14, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced that The Board of Directors has voted to declare a dividend of $0.25 per quarter. The dividend will be paid to shareholders of record on July 28, 2008. The dividend will be paid Wednesday, August 27. The Company last paid a dividend in 1996. It is the intention of the company to maintain a quarterly dividend policy if net profits are available to maintain the dividend.

The Company expects that the distribution will be treated, for Federal income tax purposes, as a "dividend". However, this determination cannot be made until shortly after the close of the taxable year at which time the Company's "earnings and profits" for 2008 will be tabulated. It is possible, though not expected, depending on the results of operations for 2008, that all or a portion of the distribution will be classified as a "return of capital". Any portion of the distribution that is properly classified as a dividend for such Federal income tax purposes will reduce the corporation's "undistributed personal holding company income" and, hence, will diminish its potential liability for personal holding company taxes.

The Company is continuing to build-out its manufacturing facilities in Oak Ridge, Tennessee which is comprised of two separate 10,000 sq. ft. buildings.

The Company continues its R&D efforts to work on the development of an automated total body albumin analyzer. Albumin is a major protein within the blood that can be used to help support the circulation in patients with acute blood loss. Up to the present time there has been no available instrument to measure the total amount of this important protein within the body which has resulted in significant under utilization of albumin administration in situations where it could help prevent collapsed circulation.

In addition, there are ongoing studies on the utilization of the BVA-100 Blood Volume Analyzer in Critical Care Medicine which are nearing completion and will be ready for submission for publication in peer reviewed medical journals.

For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh (COO) at 212-330-8515, stephen@daxor.com or Diane Meegan (Investor Relations) at 212-330-8512, dmeegan@daxor.com.

Contact Information